Biotech New Lows: ArQule (NASDAQ:ARQL), OvaScience Inc (NASDAQ:OVAS), Uniqure (NASDAQ:QURE), Egalet Corp (NASDAQ:EGLT)

ArQule Inc. (NASDAQ:ARQL) announced that the Company will present at the Needham 13th Annual Healthcare Conference. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.92% in last session and finished the day at $1.66. Traded volume was 530,559.00million shares in the last session and the average volume of the stock remained 389.39K shares. The beta of the stock remained 1.31. ArQule, Inc. (NASDAQ:ARQL) insider ownership is 0.90%.

One stock that might be an intriguing choice for investors right now is OvaScience, Inc Inc (NASDAQ:OVAS). This is because this security in the Med-Biomed/Generic industry space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. OvaScience Inc (NASDAQ:OVAS) dropped -4.77 percent to $7.78 Thursday on volume of 141,395.00million shares. The intra-day range of the stock was $7.72 to $8.25. OvaScience Inc (NASDAQ:OVAS) has a market capitalization of $187.67million.

Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, announced the appointment of Eric Goossens as its new Chief Operating Officer with a primary responsibility for manufacturing and project management. Uniqure NV (NASDAQ:QURE)’s stock on Apr 17, 2014 reported a decrease of -1.15% to the closing price of $9.00. Its fifty two weeks range is $8.51 -$18.75. The total market capitalization recorded $151.15million. The overall volume in the last trading session was 119,242.00million shares. In its share capital, QURE has 17.59million outstanding shares.

“We have created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient (API). Using our proprietary platform, Egalet Corporation (NASDAQ:EGLT) has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical manipulation, while also providing tailored release of the active pharmaceutical ingredient” said by Egalet Corporation (NASDAQ:EGLT)’s chief executive Bob Radie in an interview. On Thursday, shares of Egalet Corp (NASDAQ:EGLT) dropped -3.15% to close the day at $9.84. Company return on investment (ROI) is 46.90% and its monthly performance is recorded as -43.84%.